Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT04611152 · Kodiak Sciences Inc · PHASE3 · terminated · last registry update 2024-08-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study did not meet primary endpoint” | – | Registry record, Kodiak Sciences Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VEGFA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-08-19Phase 3 first posted: Clinique de Retine de l'est, a drug against VEGFA (NCT07129239)
- 2025-08-05Results posted on the registry: Unity Biotechnology, Inc., Aflibercept + foselutoclax (NCT06011798)
- 2025-08-05Results posted on the registry: Opthea Limited, 2.0 mg OPT-302 + 2.0 aflibercept (NCT04757636)
- 2025-08-05Also stopped (terminated): Opthea Limited, 2.0 mg OPT-302 + 2.0 aflibercept (NCT04757636)
- 2025-07-22Results posted on the registry: Opthea Limited, 2.0 mg OPT-302 + 0.5 mg ranibizumab (NCT04757610)
- 2025-07-22Also stopped (terminated): Opthea Limited, 2.0 mg OPT-302 + 0.5 mg ranibizumab (NCT04757610)
- 2025-07-15Phase 3 first posted: 4D Molecular Therapeutics, 4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL) (NCT07064759)
- 2025-07-10Results posted on the registry: Adverum Biotechnologies, Inc., 6E11 vg/eye of ADVM-022 + 2E11 vg/eye of ADVM-022 (NCT04418427)
- 2025-06-05Phase 3 first posted: AbbVie, Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab Control (NCT07007065)
- 2025-05-22Phase 3 first posted: Belfast Health and Social Care Trust, Anti-VEGF Monotherapy (standard care) (NCT06985706)
- 2025-05-04Phase 3 first posted: EyeBiotech Ltd., Remigromig + Ranibizumab (NCT06957080)
- 2025-04-30Phase 3 first posted: Parc de Salut Mar, Bevacizumab + Ranibizumab Ophthalmic (NCT06952452)
- 2025-03-13Also stopped (terminated): IVERIC bio, Inc., Avacincaptad Pegol + Avastin (NCT05571267)
- 2025-03-07Phase 3 first posted: 4D Molecular Therapeutics, 4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL) (NCT06864988)
- 2025-03-04Phase 3 first posted: Adverum Biotechnologies, Inc., Ixo-vec + Aflibercept (NCT06856577)
- 2025-02-26Phase 3 first posted: Hoffmann-La Roche, Ranibizumab (NCT06847542)
- 2025-02-24Results posted on the registry: Novartis Pharmaceuticals, Brolucizumab (NCT04774926)
- 2025-02-24Results posted on the registry: Wake Forest University Health Sciences, Aflibercept Ophthalmic (NCT04707625)
- 2025-02-24Also stopped (terminated): Wake Forest University Health Sciences, Aflibercept Ophthalmic (NCT04707625)
- 2025-02-14Results posted on the registry: Amgen, ABP 938 + Aflibercept (NCT05704725)
- 2025-02-05Results posted on the registry: John Hays, aflibercept + oxaliplatin (NCT01652196)
- 2025-01-27Results posted on the registry: Novartis Pharmaceuticals, Brolucizumab (NCT04679935)
- 2025-01-24Phase 3 first posted: Jaeb Center for Health Research, Faricimab (NCT06790784)
- 2024-12-30Results posted on the registry: Samsung Bioepis Co., Ltd., SB11 PFS (NCT06176963)
- 2024-12-10Results posted on the registry: Novartis Pharmaceuticals, Injection Brolucizumab (NCT05269966)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision